TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6433715

Group type: EXPERIMENTAL
Intervention: Sensory stimulation therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Staff attention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard hospital treatment
Number of subjects: 30
Study: 30702365

Group type: EXPERIMENTAL
Intervention: Peer Navigator (PN) intervention providing individualized support with advance care planning, care coordination, and counseling about diet and mental health.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Peer Navigator (PN) intervention
Number of subjects: 40
Study: 29725702

Group type: EXPERIMENTAL
Intervention: Menthol Vuse Solo electronic cigarettes (14, 29, and 36 mg nicotine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menthol Vuse Solo electronic cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menthol cigarettes
Number of subjects: 0
Study: 26266775

Group type: EXPERIMENTAL
Intervention: Expected electrical pain stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unexpected electrical pain stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nonpainful stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sham stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resting alert state
Number of subjects: 20
Study: 24972761

Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention (one-question SMS message at 9:30 am or 6:30 pm for 7 days)
Number of subjects: 59
Study: 22399124

Group type: EXPERIMENTAL
Intervention: 50 mg/kg i.v. Magnesium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 60
Study: 20564086

Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 0
Study: 17628351

Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: counseling+transfer
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: counseling+methadone
Number of subjects: 211
Study: 15894961

Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 88

Group type: COMPARATOR
Intervention: Noninvasive management
Number of subjects: 88
Study: 12355576

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) as a topically applied photosensitizer for photodynamic therapy (PDT) with a fixed dose of ALA (200 mg/ml) and escalating radiant energies (50-150 J/cm(2)).
Number of subjects: 40
Study: 10930200

Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 101

Group type: COMPARATOR
Intervention: ETT
Number of subjects: 101
Study: 8820833

Group type: EXPERIMENTAL
Intervention: Test group (first-shock energy programmed at 2 X DFT+, second to fifth shocks at maximum output 34 J)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (all shocks programmed at 34 J)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pooled data from both groups
Number of subjects: 162
Study: 1568519

Group type: EXPERIMENTAL
Intervention: Sulodexide (500 lipoproteinlipase releasing units twice daily for 1 month)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3917968

Group type: EXPERIMENTAL
Intervention: Parenteral amino acid-glucose solution for 1 month
Number of subjects: 15

Group type: COMPARATOR
Intervention: Glucose solution without amino acids
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (Amino acid and Control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Parenteral amino acid-glucose solution
Number of subjects: 15
Study: 30871480

Group type: EXPERIMENTAL
Intervention: Guided Self‐rehabilitation Contract
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 124
Study: 28338406

Group type: EXPERIMENTAL
Intervention: Physical Activity Feedback (PAF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 45
Study: 27102820

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24895381

Group type: EXPERIMENTAL
Intervention: 12-week balance training programme (3 times per week)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 22456062

Group type: EXPERIMENTAL
Intervention: Ultrasound only monitoring group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound plus serum estradiol and progesterone monitoring group
Number of subjects: 0
Study: 20662726

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (personalized Mediterranean diet, physical activity increase, smoking withdrawal counseling)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (159 patients)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 156
Study: 18760151

Group type: EXPERIMENTAL
Intervention: Twelve-week intensive progressive strength-power training (n=24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No intervention (control group, n=22)
Number of subjects: 46
Study: 15903362

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 minutes of continuous cycling at 70% of Vo(2)max)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anaerobic exercise (intermittent dumbbell squatting at 70% of 1 repetition maximum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both aerobic and anaerobic exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (pre-exercise measurements)
Number of subjects: 10
Study: 12620945

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) with propofol 2.5 mg x kg(‐1) and fentanyl 1 micro g x kg(‐1) maintained with N(2)O‐O(2) 50:50 and desflurane for 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka and orange juice to reach BAC 0.08%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 12
Study: 10488296

Group type: EXPERIMENTAL
Intervention: Midazolam (0.540 microgram/kg per minute with fentanyl and 50% nitrous oxide)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sevoflurane (1.4% end-tidal concentration with fentanyl and 50% nitrous oxide)
Number of subjects: 101
Study: 8763803

Group type: EXPERIMENTAL
Intervention: Patient Centred and Self-Directive (PCSD) intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional Care (CC)
Number of subjects: 115
Study: 29425120

Group type: EXPERIMENTAL
Intervention: Low-fat plant-based diet (n = 38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no diet changes, n = 37)
Number of subjects: 75
Study: 27222733

Group type: EXPERIMENTAL
Intervention: Remotely monitored adherence
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dose counter adherence
Number of subjects: 184

Group type: COMPARATOR
Intervention: Good adherence
Number of subjects: 184
Study: 24609847

Group type: EXPERIMENTAL
Intervention: Culturally appropriate education intervention
Number of subjects: 415

Group type: COMPARATOR
Intervention: General health education (control)
Number of subjects: 415
Study: 22403047

Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study: 19811806

Group type: EXPERIMENTAL
Intervention: Stented group with a Double‐J stent fixed pre‐ESWL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-stented group treated by in situ ESWL
Number of subjects: 60
Study: 17696126

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg (n = 627)
Number of subjects: 2113

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a plus natalizumab 300 mg (n = 589)
Number of subjects: 2113

Group type: COMPARATOR
Intervention: Placebo (n = 315)
Number of subjects: 2113

Group type: COMPARATOR
Intervention: Interferon beta‐1a plus placebo (n = 582)
Number of subjects: 2113
Study: 15877671

Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoetin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravenous darbepoetin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both routes
Number of subjects: 53
Study: 12468578

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (Healthy Normotensive Volunteers)
Number of subjects: 21
Study: 9796239

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia with 8 mg of 0.5% hyperbaric bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with bilateral spinal anaesthesia using 15 mg of 0.5% hyperbaric bupivacaine
Number of subjects: 30
Study: 7638814

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2533763

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg three doses by mouth)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg three doses by mouth)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 322787

Group type: EXPERIMENTAL
Intervention: Extraperitoneal wound drainage
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Prophylactic systemic cephaloridine
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Extraperitoneal wound drainage + Prophylactic systemic cephaloridine
Number of subjects: 246
Study: 31109415

Group type: EXPERIMENTAL
Intervention: Middle MAP group (65 mmHg ≤ MAP < 70 mmHg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low MAP group (60 mmHg ≤ MAP < 65 mmHg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High MAP group (70 mmHg ≤ MAP < 75 mmHg)
Number of subjects: 60
Study: 28153215

Group type: EXPERIMENTAL
Intervention: Integrative mind-body-spirit intervention (I-BMS)
Number of subjects: 126
Study: 26258314

Group type: EXPERIMENTAL
Intervention: 6MHP vaccine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 127
Study: 23793226

Group type: EXPERIMENTAL
Intervention: Ayahuasca intake
Number of subjects: 24
Study: 21751661

Group type: EXPERIMENTAL
Intervention: Interval training programme (n = 140; 8 weeks, 60-79% HR max reserve, 45-60 minutes, work/rest ratio of 1:1)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (n = 105; sedentary)
Number of subjects: 245
Study: 19383438

Group type: EXPERIMENTAL
Intervention: True needling
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 18

Group type: COMPARATOR
Intervention: Overt control (placebo)
Number of subjects: 18
Study: 16531619

Group type: COMPARATOR
Intervention: Vascular brachytherapy (n = 125)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (n = 259)
Number of subjects: 384
Study: 12777368

Group type: EXPERIMENTAL
Intervention: Tick-related educational materials
Number of subjects: 317

Group type: COMPARATOR
Intervention: General health-related educational materials
Number of subjects: 317
Study: 10701035

Group type: EXPERIMENTAL
Intervention: 1% lignocaine 1.6 ml and 4 mg morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1% lignocaine 2 ml
Number of subjects: 20
Study: 9382669

Group type: EXPERIMENTAL
Intervention: Screening for low bone density
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening (Control)
Number of subjects: 0
Study: 8260181

Group type: EXPERIMENTAL
Intervention: Serum tetranectin levels
Number of subjects: 67
Study: 3517321

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28256778

Group type: EXPERIMENTAL
Intervention: Rechargeable implantable pulse generators (rIPGs) implanted at the next IPG depletion after 2007 until 2012.
Number of subjects: 10
Study: 27429413

Group type: EXPERIMENTAL
Intervention: Simulation intervention (6.5min video related to healthcare acquired infection and 4 simulated situations requiring hand hygiene)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (received the same lecture pertaining to hand hygiene)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Assessment of hand hygiene technique using Glo Germ and UV photography
Number of subjects: 131
Study: 21574837

Group type: EXPERIMENTAL
Intervention: GapSeal gel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: O‐ring
Number of subjects: 45

Group type: COMPARATOR
Intervention: Unsealed group
Number of subjects: 45
Study: 22374870

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 829

Group type: COMPARATOR
Intervention: No prednisolone treatment (Control)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Sunnybrook score at baseline
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Sunnybrook score at days 11 to 17
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Sunnybrook score at 1 month
Number of subjects: 829
Study: 21250567

Group type: EXPERIMENTAL
Intervention: NaF/triclosan/copolymer dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: MFP dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice
Number of subjects: 0
Study: 18328136

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 16279817

Group type: EXPERIMENTAL
Intervention: Intraoral appliance (IOA) using superelastic coils
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extraoral appliance (EOA) (cervical headgear)
Number of subjects: 40
Study: 11867979

Group type: EXPERIMENTAL
Intervention: Graphic method for gastric tube depth of insertion
Number of subjects: 88

Group type: COMPARATOR
Intervention: NEX method for gastric tube depth of insertion
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Graphic method (absolute values)
Number of subjects: 88

Group type: COMPARATOR
Intervention: NEX method (absolute values)
Number of subjects: 88
Study: 10467970

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 7825534

Group type: EXPERIMENTAL
Intervention: Diet A (12% of total energy intake)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diet B (21% of total energy intake)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of PT rates between men and women
Number of subjects: 28
Study: 2354694

Group type: EXPERIMENTAL
Intervention: gari as eba 50 g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: lafun 50 g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: parboiled cassava flakes 76 g
Number of subjects: 11

Group type: COMPARATOR
Intervention: 75 g glucose
Number of subjects: 11
Study: 6254456

Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30339035

Group type: EXPERIMENTAL
Intervention: Diet-Exercise trainings with creative drama method
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 76
Study: 29620558

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) strength training (n=16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) strength training (n=16)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n=16) with no specific exercise programme
Number of subjects: 48
Study: 28974267

Group type: EXPERIMENTAL
Intervention: Multi-component exercise programme and nutritional supplementation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 51
Study: 26665746

Group type: EXPERIMENTAL
Intervention: Art Therapy (AT) in addition to Psychotherapy (PT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Psychotherapy (PT) alone
Number of subjects: 141
Study: 23980737

Group type: EXPERIMENTAL
Intervention: CET (Concurrent Exercise Training)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: RET (Resistance Exercise Training)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: EET (Endurance Exercise Training)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: All training interventions
Number of subjects: 47
Study: 21802150

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Risperidone (RIS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no concomitant mood stabilizers)
Number of subjects: 160
Study: 19109574

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.0 mg/kg/day)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Methotrexate (0.3 mg/kg/week, increased to 25 mg/week)
Number of subjects: 126
Study: 17146324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 4.5 mg.kg caffeine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 9.0 mg.kg caffeine
Number of subjects: 6
Study: 12710402

Group type: EXPERIMENTAL
Intervention: VaxGen vaccine
Number of subjects: 0
Study: 10671332

Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg orally twice daily)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 9085974

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 7693932

Group type: EXPERIMENTAL
Intervention: Peroperative cholangiography (PC)
Number of subjects: 285

Group type: COMPARATOR
Intervention: No peroperative cholangiography (Control group)
Number of subjects: 285
Study: 3964534

Group type: EXPERIMENTAL
Intervention: Neat oil suspension (Sandimmun)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Milk as dispersant
Number of subjects: 12

Group type: COMPARATOR
Intervention: Milk + chocolate flavouring as dispersant
Number of subjects: 12

Group type: COMPARATOR
Intervention: Orange juice as dispersant
Number of subjects: 12
Study: 29602814

Group type: EXPERIMENTAL
Intervention: Limited respiratory monitoring (LRM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 14
Study: 29936921

Group type: EXPERIMENTAL
Intervention: Liquid ubiquinol (100 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 27083776

Group type: EXPERIMENTAL
Intervention: Intervention Arm A (invitation letter)
Number of subjects: 5265

Group type: COMPARATOR
Intervention: Control Arm C (no invitation)
Number of subjects: 5265

Group type: EXPERIMENTAL
Intervention: Excluding women who participated in screening annually
Number of subjects: 5265
Study: 26569364

Group type: EXPERIMENTAL
Intervention: Circulating levels of miR‐199a‐3p, miR‐423‐3p, and miR‐let‐7i‐5p
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Increase in creatinine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Increase in NGAL
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: MiR‐199a‐3p
Number of subjects: 98
Study: 22721373

Group type: EXPERIMENTAL
Intervention: Training condition (participants exposed to the Target Object)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (participants not exposed to the Target Object)
Number of subjects: 0
Study: 20393402

Group type: EXPERIMENTAL
Intervention: 35 mg risedronate weekly, vitamin D, and calcium
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (vitamin D and calcium only)
Number of subjects: 101
Study: 18706096

Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 120

Group type: COMPARATOR
Intervention: WL
Number of subjects: 120
Study: 15917045

Group type: EXPERIMENTAL
Intervention: Healthy Eating and Lifestyle Program (10 weekly weight loss classes)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Further group counseling or staff-facilitated self-help (Phase 2)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Overall (baseline to final visit; average 18 months total duration)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (follow-up clinic visits only)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Completers of the program
Number of subjects: 237
Study: 12526935

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 14 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day for 14 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PPI treatment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BreathID
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 52
Study: 10685198

Group type: EXPERIMENTAL
Intervention: Delayed pushing protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (directed pushing at full cervical dilation)
Number of subjects: 0
Study: 8595542

Group type: EXPERIMENTAL
Intervention: Acrivastine + pseudoephedrine
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Acrivastine
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 3190996

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 600 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 900 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 1200 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Aspirin tablet 1200 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Aspirin tablets 600 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Aspirin tablets 900 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Soluble aspirin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 1136678

Group type: EXPERIMENTAL
Intervention: Muscular exercise programme
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no muscular exercise)
Number of subjects: 27
Study: 31891553

Group type: EXPERIMENTAL
Intervention: Interportal capsulotomy with closure (CC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Interportal capsulotomy without closure (IC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: T-capsulotomy without closure (TC)
Number of subjects: 150